The Preoperative Sequential Administration of GM-CSF and IL-2 at the Primary Site of Cutaneous Melanoma Can Induce Immense Specific Antitumor Response: A potential New Approach to Adjuvant Immunotherapy

The outlook for patients with metastatic melanoma is very poor. Therefore, every effort should be made to control the disease at its initial stage and at the time of the diagnosis. Several adjuvant therapeutic approaches administered systemically after tumor resection failed to have any major impact on melanoma. This clearly indicates that new adjuvant therapeutic approaches are needed, administered at relatively early stages of the disease to prevent disease recurrence and metastases.